Scarica l'app Stockscreener
5.945
10.20%
-0.675
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio stock drops 10% Friday, then pops after hours as IBRX heads into a holiday break - Bez Kabli
IBRX Stokes Retail Chatter — Investors See Anktiva Beat Merck’s Keytruda With Approval In EU - Stocktwits
ImmunityBio (NASDAQ:IBRX) Trading Down 10.1%Time to Sell? - MarketBeat
Top 10 Most Shorted Stocks: CleanSpark, Hims & Hers And More - Benzinga
ImmunityBio Stock Faces Uncertainty Amid Market Volatility - timothysykes.com
ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX) - MarketBeat
Is ImmunityBio Inc Gaining or Losing Market Support? - Benzinga
Will ImmunityBio Inc. outperform tech stocksRate Cut & AI Driven Price Predictions - mfd.ru
ImmunityBio (NASDAQ:IBRX) Stock Price Up 1.2%What's Next? - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
Behind the Scenes of ImmunityBio's Latest Options Trends - Benzinga
A Look At ImmunityBio (IBRX) Valuation After ASCO 2026 Spotlight And Anktiva Growth Momentum - Yahoo Finance
Is It Too Late To Consider ImmunityBio (IBRX) After The Recent 181% Monthly Surge? - Yahoo Finance
ImmunityBio Advances Chemotherapy Free Lymphoma Regimen As Global Anktiva Story Grows - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Trading Down 5.3%Here's Why - MarketBeat
ImmunityBio (IBRX) jumps ahead of oncology event - MSN
ImmunityBio (IBRX) Jumps Ahead of Oncology Event - Finviz
ImmunityBio Shares Gain Momentum on Strong Sales and Regulatory Progress - AD HOC NEWS
ImmunityBio's Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC) - openPR.com
ImmunityBio stock steadies near $7 after 15% jump; earnings next up - TechStock²
ImmunityBio, Inc. (IBRX) Investor Outlook: Analyzing the 70% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
ImmunityBio (NASDAQ:IBRX) Trading 14.5% HigherHere's What Happened - MarketBeat
ImmunityBio Surge After Saudi Approvals and FDA Meeting - Hoodline
ImmunityBio’s Stock Soars on Promising Trial Results and Strategic Advances - StocksToTrade
New Sign-Off Propels ImmunityBio - Los Angeles Business Journal
ImmunityBio rally causes $492M paper losses for short sellers - MSN
Did ImmunityBio’s (IBRX) New Chemotherapy‑Free CAR‑NK Phase 2 Trial Just Redefine Its Investment Narrative? - Sahm
Aug Ideas: Does ImmunityBio Inc have a competitive edgeOil Prices & Weekly Setup with ROI Potential - baoquankhu1.vn
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ImmunityBio (NASDAQ:IBRX) Shares Up 7.3%Still a Buy? - MarketBeat
ImmunityBio initiates another cell therapy trial with no chemotherapy needs - MSN
ImmunityBio (NASDAQ:IBRX) Trading Down 4.1%What's Next? - MarketBeat
ImmunityBio Accelerates Pipeline with New Lymphoma Trial Amid Stellar Revenue Forecast - AD HOC NEWS
ImmunityBio (NASDAQ:IBRX) Stock Price Down 7.1%What's Next? - MarketBeat
Soon-Shiong, ImmunityBio Exit Challenge to Cancer Drug Financing - Bloomberg Law News
ImmunityBio extends gains after FDA views on Anktiva label expansion - MSN
ImmunityBio Stockholder Targets Soon-Shiong In Chancery - Law360
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.3%Should You Buy? - MarketBeat
Soon-Shiong Defends ImmunityBio Financing Pact for Cancer Drug - Bloomberg Law News
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients - MSN
ImmunityBio Shares Maintain Upward Momentum on Clinical and Commercial Progress - AD HOC NEWS
ImmunityBio Stock Maintains Momentum with New Clinical Trial - AD HOC NEWS
ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy By Investing.com - Investing.com Nigeria
ImmunityBio (NASDAQ:IBRX) Trading Down 1.9%Should You Sell? - MarketBeat
Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs - Stocktwits
Piper Sandler see label expansion potential for ImmunityBio, Inc. (IBRX)’s Anktiva following Quilt data - MSN
Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data - Yahoo Finance
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas - BioSpace
ImmunityBio Launches Phase 2 Study of Cell Therapy in Indolent Lymphomas - marketscreener.com
ImmunityBio launches phase 2 chemotherapy-free car-nk cell therapy trial with Anktiva - marketscreener.com
ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy - Investing.com
ImmunityBio Stock: Commercialization Efforts Accelerate Following Key Approvals - AD HOC NEWS
ImmunityBio shares jump after constructive FDA talks on bladder cancer therapy - MSN
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock - TechStock²
ImmunityBio (IBRX) sheds 4% on profit-taking after 14-day run - MSN
Did ANKTIVA’s Expanding Approvals and Chemo‑Free GBM Data Just Shift ImmunityBio’s (IBRX) Investment Narrative? - Sahm
Biotech Stocks To Keep An Eye OnJanuary 31st - MarketBeat
Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - MSN
Clinical Promise and Regulatory Scrutiny Collide for ImmunityBio - AD HOC NEWS
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
ImmunityBio Stock Surges on Clinical and Commercial Momentum - AD HOC NEWS
ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX - TechStock²
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):